DelveInsights, “Insight into the major depressive disorder pipeline2022″, The report provides comprehensive insights into Over 75 companies and over 75 drugs in the pipeline in the pipeline landscape for Major Depressive Disorder. It covers the pipeline drug profiles, including both clinical and non-clinical stage products. It also includes therapeutic evaluation by product type, stage, route of administration and molecule type. It also highlights the inactive pipeline products in this space.

Key Takeaways from the Major Depressive Disorder Pipeline Insight Report

• DelveInsight’s Major Depressive Pipeline Report shows a robust realm with over 75 active stakeholders working to develop more than 75 pipeline therapies for major depressive disorder.
• The major major depressive disorder companies such as GH Research, Praxis Precision Medicines, AbbVie, Luye Pharma Group, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, XWPharma, Reviva Pharmaceuticals, Gate Neurosciences, Sirtsei Pharmaceuticals Seelos Therapeutics, Chase Therapeutics, Clexio Biosciences Ltd, VistaGen Therapeutics, Neuralstem, BioLite, Neurocrine Biosciences, MindMed, BioGen, Alector and Chase Therapeutics, Cybin and others are evaluating the Novel drug candidate to treat major depression to improve the treatment landscape.
• Major pipeline therapies for major depression at various stages of development include AXS-05, LY-03005, MIN-202, SAGE-217, REL-1017, CAPLYTA, PRAX 114, GH001, NBI-1065845, PH 10A, XW 10508 RP – 5063, Zelquistinel, Apimostinel, SP-624, SLS-002, CTC-501 CLE-100, AV 101, OPC-64005, PDC 1421, NBI-1065845, MM-120, Zuranolone, AL001, SPL026, CTC-413, CYB003 , GH001 and others.
• The companies and scientists are working to assess challenges and seek opportunities that could impact major depression research and development. The therapies under…